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Assessment of the Tissue Distribution of Transplanted
Human Endothelial Progenitor Cells by
Radioactive Labeling
Alexandra Aicher, MD*; Winfried Brenner, MD*; Maaz Zuhayra, PhD; Cornel Badorff, MD;
Schirin Massoudi, MD; Birgit Assmus, MD; Thomas Eckey; Eberhard Henze, MD;
Andreas M. Zeiher, MD; Stefanie Dimmeler, PhD
Background—Transplantation of endothelial progenitor cells (EPCs) improves vascularization and left ventricular function
after experimental myocardial ischemia. However, tissue distribution of transplanted EPCs has not yet been monitored
in living animals. Therefore, we tested whether radioactive labeling allows us to detect injected EPCs.
Methods and Results—Human EPCs were isolated from peripheral blood, characterized by expression of endothelial
marker proteins, and radioactively labeled with [111In]indium oxine. EPCs (106) were injected in athymic nude rats 24
hours after myocardial infarction (n58) or sham operation (n58). Scintigraphic images were acquired after 1, 24, 48,
and 96 hours after EPC injection. Animals were then killed, and specific radioactivity was measured in different tissues.
At 24 to 96 hours after intravenous injection of EPCs, ’70% of the radioactivity was localized in the spleen and liver,
with only ’1% of the radioactivity identified in the heart of sham-operated animals. After myocardial infarction, the
heart-to-muscle radioactivity ratio increased significantly, from 1.0260.19 in sham-operated animals to 2.0360.37 after
intravenous administration of EPCs. Injection of EPCs into the left ventricular cavity increased this ratio profoundly,
from 2.6961.54 in sham-operated animals to 4.7061.55 (P,0.05) in rats with myocardial infarction. Immunostaining
of cryosections from infarcted hearts confirmed that EPCs homed predominantly to the infarct border zone.
Conclusions—Although only a small proportion of radiolabeled EPCs are detected in nonischemic myocardium,
myocardial infarction increases homing of transplanted EPCs in vivo profoundly. Radiolabeling might eventually
provide an useful tool for monitoring the fate of transplanted progenitor cells and for clinical cell therapy. (Circulation.
2003;107:2134-2139.)
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Endothelial progenitor cells (EPCs) can contribute toneovascularization of ischemic heart tissue. Infusion of
ex vivo–cultivated EPCs was shown to improve vasculariza-
tion and left ventricular function after myocardial ischemia.1,2
The integration of EPCs into the neovasculature of ischemic
regions has been documented by use of immunohistochemi-
cal staining of tissue sections.1–3 Biodistribution of trans-
planted EPCs in vivo was followed up either by uptake of red
fluorescence–labeled acetylated LDL (DiLDL) or by genetic
modifications introducing genes for fluorochromes or meta-
bolic enzymes.2,4,5 However, detection of fluorescence or
enzyme-produced colorimetric reactions is a laborious pro-
cess limited by the need to take biopsies or kill the animal,
which precludes its use in humans. In addition, immunohis-
tochemical analysis of tissue sections is severely limited to
assess the temporal course of homing and tissue distribution
of transplanted cells within the whole body. Therefore, the
development of noninvasive imaging approaches for moni-
toring the fate and tissue distribution of transplanted progen-
itor cells is required.
One approach to track the distribution pattern of in vivo–
injected cells is the monitoring of cells after radiolabeling.
[111In]indium oxine (111In-oxine) has been widely accepted for
safe radiolabeling of leukocytes to localize areas of inflam-
mation.6–8 Moreover, 111In-oxine has been used to determine
the biodistribution of transplanted hepatocytes9 or dendritic
cells.10,11 Therefore, we investigated whether radioactive
labeling with 111In-oxine might provide a clinically applicable
tool to monitor the fate of transplanted EPCs in living rats
after myocardial infarction. Moreover, we examined whether
the route of administration, ie, intravenous versus left ven-
tricular intracavitary application, affects myocardial incorpo-
ration of EPCs.
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Methods
Cell Culture
Ex vivo expansion of EPCs was performed according to Vasa et al12
in a modification that also used 50 ng/mL vascular endothelial
growth factor (Peprotech), 20 ng/mL basic fibroblast growth factor
(R&D), and 0.1 mmol/L atorvastatin (Pfizer). Vascular endothelial
growth factor, basic fibroblast growth factor, and atorvastatin were
used to increase EPC numbers as described previously.12,13
Fluorescence and Radioactive Labeling
Adherent EPCs were detached with 1 mmol/L EDTA, pH 7.4, for 15
minutes at 37°C. After a washing with PBS, the pelleted cells were
adjusted to 63106/mL and labeled with 4 mg/mL DiLDL for 20
minutes at 37°C. EPCs were washed with PBS and resuspended in
growth factor and serum-free endothelial basal medium (EBM).
Then 106 EPCs/mL were labeled with 15 MBq of 111In-oxine
(physical half-life, 2.8 days; g-energy, 171 keV, 245 keV; 37
MBq/mL; Mallinckrodt) for 60 minutes at 37°C. To remove excess
unbound radioactivity, cells were washed twice. Labeling efficiency
was measured with a dose calibrator (Atomlab 100, Biodex Medi-
cal). Before injection, EPCs were resuspended in 0.5 mL serum-free
EBM in 1.0-mL syringes with 27-gauge needles.
Assessment of Cell Viability
LDH release (cytotoxicity detection kit [LDH], Roche) in the
supernatants of 111In-oxine–labeled cells was measured to evaluate
cell death and compared with untreated controls.
DiLDL uptake as a functional assay for EPC viability was
performed. 111In-oxine–labeled EPCs underwent DiLDL labeling and
were fixed in 2% formaldehyde. The number of DiLDL1 cells was
determined with a fluorescence microscope (Axiovert 100 M, Zeiss)
and evaluated by counting 3 randomly selected high-power fields.
Migration Assay
Migration assays were performed with 23104 radiolabeled or unla-
beled EPCs in 0.2 mL EBM that were seeded into the top chamber
of a modified Boyden chamber, as described previously.12
Animal Experiments
Because of the transplantation of human EPCs into a xenogeneic rat
model, immunodeficient athymic rnu:rnu rats (5- to 7-week-old
females; Charles River, Sulzfeld, Germany) were required. Animals
were anesthetized with intramuscular ketamine (100 mg/kg;
Curamed) and midazolam (2 mg/kg; Hoffmann-La-Roche). To
prevent arrhythmias after cardiac surgery, intramuscular amiodarone
(5 mg/kg; Sanofi-Sythelabo) was given prophylactically. An endo-
tracheal tube (17-gauge) was inserted for volume-controlled venti-
lation of the animals. Open-chest cardiac surgery was performed
after left thoracotomy to occlude the left coronary artery by passing
a 5-0 suture just under the tip of the left auricle (n58). Sham-treated
animals underwent left thoracotomy and incision of the pericardium
(n58). To reduce postoperative pain, piritramide (2 mg/kg; Janssen-
Cilag) was administered. After the chest wound was closed, rnu:rnu
rats were allowed to recover for 24 hours before injection of EPCs.
DiLDL and 111In-oxine–labeled EPCs were given either by intrave-
nous application into the lateral tail vein (n58) or with a x-ray-
assisted transdiaphragmatic approach for administration into the left
ventricular cavity (n58). Before the latter procedure, contrast
medium (Isovist, Schering) was injected transdiaphragmatically into
the heart to check left ventricular position under radiographic
control. Furthermore, 3 additional animals received free 111In-oxine
as radioactivity-positive controls.
Scintigrams of the animals were acquired immediately after tracer
injection with a double-headed gamma camera (ECAM, Siemens)
equipped with a pinhole collimator with an inset for medium energy.
The energy windows were centered at 171 keV610% and 245
keV610%.
All animal experiments were performed with approved consent by
the Animal Research Committee at the University of Kiel in
accordance with federal law (V 252-72241.122-17).
Tissue Preparation and Immunostaining
Hearts of the euthanized animals were perfused with heparinized
saline through the cannulated abdominal aorta. Transverse slices of
the base, midregion, and apex of the hearts as well as tissue samples
from other organs, such as skeletal muscles, lungs, kidneys, liver,
and spleen, were obtained. All specimens were weighed, and the
count rate was measured in a lead-shielded and calibrated well
counter (LB 5310, Berthold) to calculate the specific activity per
gram tissue sample after correction for radioactive decay. Further-
more, organ samples were mounted in OCT compound (TissueTek,
Sakura) and snap-frozen in liquid nitrogen. Sections (5 mm) were
then cut and examined for red fluorescent DiLDL-labeled EPCs in
the native specimens. To confirm the human origin of the EPCs
found in the frozen tissue sections, we used FITC- or phycoerythrin-
labeled anti-HLA class I (1:50; Caltag) that specifically recognizes
human but not rat major histocompatibility class I molecules. In
addition, double-staining with rhodamine-labeled Ulex europaeus
lectin (1:150; Vector Laboratories) was performed to confirm the
endothelial character of the detected cells. Destruction of cardiac
myocytes after myocardial infarction was visualized by staining of
myocytes with FITC-conjugated (Pierce) a-sarcomeric actinin
(1:250; Sigma). For immunostaining, sections were incubated with
the directly fluorochrome-conjugated antibodies for 1 hour at room
temperature. PBS was used for washing between the subsequent
incubation steps. Fluorescence was visualized with an Axiovert 100
M microscope (Zeiss) equipped with a digital camera (Axiocam;
Zeiss) and imaging software (Axiovision; Zeiss).
Statistical Analysis
Data are expressed as mean6SD. Unpaired, 2-tailed t test was used
for the comparison of continuous variables. A value of P,0.05 was
considered statistically significant.
Results
In Vitro Labeling of EPCs With 111In-oxine
Human EPCs were cultivated, and the endothelial phenotype
was confirmed by demonstration of endothelial marker pro-
teins such as VE-cadherin, KDR, von Willebrand factor, and
endothelial nitric oxide synthase as previously described.12,13
To test the efficiency of the labeling, EPCs were incubated
with 15 MBq 111In-oxine in serum-free EBM between 10 and
60 minutes. A time-dependent incorporation of 111In-oxine
was observed with a maximum efficiency after 60 minutes
(Figure 1A), resulting in an overall labeling efficiency of
67613%. Next, we investigated whether the labeling affects
cell viability or function. Therefore, LDH release was mea-
sured as a marker for cell death in the cell culture supernatant.
However, up to 96 hours after 111In-oxine labeling, LDH
activity in the replated radiolabeled EPCs was not signifi-
cantly different from controls, with 96.365.7% of unlabeled
cells at 96 hours after labeling (n53). Moreover, the func-
tional activity of EPCs was assessed by DiLDL uptake. The
number of cells that actively took up DiLDL was 93.463.9%
(n53) of the number of DiLDL1 cells in unlabeled EPCs after
48 hours and 90.264.7% after 96 hours (n53). Similarly, the
functional capacity of EPCs to migrate in response to vascu-
lar endothelial growth factor in a modified Boyden chamber
assay was not affected by radiolabeling when radiolabeled
EPCs were compared with their unlabeled controls (Figure
1B). To determine the leakage of 111In into the supernatant,
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we checked the activity of 111In in the supernatants as well as
in the adherently growing EPCs. We found that 39.362.1%
of the 111In incorporated into EPCs was retained after 48 hours
and 22.067.5% after 96 hours.
Distribution of EPCs in Rats
In the first set of experiments, radioactively labeled human
EPCs were infused intravenously in sham-operated (n54) or
infarcted (n54) athymic immunodeficient nude rats. Scinti-
graphic images of the animals were acquired with a gamma
camera with pinhole collimators (Figure 2). Images were
obtained after injection and then 24, 48, and 96 hours later.
Immediately after injection of the EPCs, a high tracer
accumulation was found in the liver, kidneys, and spleen,
which increased to 71.8613.7% of the injected activity at 60
minutes. No radioactivity was visible in bones, suggesting
that EPCs do not accumulate in the bone marrow to a
significant extent within the first 24 hours. The tracer distri-
bution did not show major changes up to 96 hours after
injection, at which time 71.067.1% of the whole-body
activity was detectable in liver, kidneys, and spleen. Further-
more, there was still no bone marrow uptake. Using a pinhole
collimator, the increase in ischemia-induced heart uptake
compared with sham-operated controls is readily visible
(Figure 2). After 96 hours, animals were killed, and the
specific radioactivity was measured in different tissues.
Consistent with the in vivo images, the majority of the
radioactivity was detected in spleen and liver (Figure 3A)
after intravenous injection. In sham-operated animals, only
’1% of the injected radioactivity was detected in the heart.
The specific heart radioactivity was 954361142 cpm/g tis-
sue. The ratio of specific radioactivity of the heart compared
with peripheral skeletal muscle tissue was 1.0260.19 in
sham-operated animals. After the induction of myocardial
infarction, this ratio increased significantly, to 2.0360.37
(P,0.05) (Figure 3B) according to a specific heart activity of
28 37661851 cpm/g (P,0.05).
To investigate whether a local administration of EPCs
increased the homing of EPCs to the heart, EPCs were
injected into the left ventricular cavity. Overall, a similar
distribution of radioactive EPCs was found (Figure 3A).
However, both the heart specific radioactivity and the heart-
to-muscle specific radioactivity ratio were increased signifi-
cantly, to 24 19267097 cpm/g tissue and 2.6961.54, respec-
tively, in sham-operated animals when EPCs were injected
into the left ventricular cavity compared with intravenous
infusion (Figure 3B). Moreover, the heart-to-muscle specific
radioactivity ratio increased further, to 4.7061.55, with a
specific heart radioactivity of 57 273622 418 cpm/g tissue
(P,0.05 versus sham-operated) when EPCs were infused
Figure 1. In vitro assays using 111In-oxine–labeled EPCs. A,
Time course of labeling efficiency of EPCs with 15 MBq 111In-
oxine. B, In addition, radiolabeling did not affect functional
capacity of EPCs to migrate, as assessed by a modified Boyden
chamber assay. Data are given as mean6SD (n53).
Figure 2. Scintigraphic pinhole images of
the thorax and abdomen of nude rats
with or without (sham-operated) myocar-
dial infarction from posterior view 24
hours after injection of 111In-oxine–la-
beled EPCs. Representative scintigraphic
images are shown depicting tracer
uptake in the heart only after myocardial
infarction.
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into the left ventricular cavity in rats with previous infarction
(Figure 3B). The amount of radioactivity in the whole heart
under these conditions corresponded to ’3% of the injected
EPCs, or ’33104 EPCs.
In animals treated with 111In-oxine (n53) alone, a different
tracer distribution (data not shown) was observed with a high
blood pool activity up to 96 hours after injection because of
the strong affinity of oxine to serum transferrin. According to
the scintigrams, blood samples showed a .25-fold higher
specific blood activity compared with animals treated with
111In-oxine–labeled EPCs.
In rats without any surgical pretreatment (n53), no signif-
icant differences were found for the specific heart radioactiv-
ity compared with sham-operated animals. These findings
exclude the operation itself as a reason for the cardiac homing
of EPCs as observed in sham-operated and infarcted animals.
Detection of EPCs by DiLDL Fluorescence
and Immunostaining
To confirm the results obtained by measuring the radioactiv-
ity and to gain further insights into the morphology of the
EPCs in the different tissues, tissue sections were analyzed.
Therefore, EPCs were incubated with DiLDL before radio-
active labeling was performed to allow for detection of
DiLDL labeling in fluorescence microscopy. Moreover,
EPCs were also detected by immunostaining with anti–
human HLA antibodies. EPCs were rarely found in the heart
of sham-operated animals (data not shown). In contrast,
hearts of infarcted rats revealed positive staining for DiLDL
and human HLA (48.3621 EPCs per infarct zone; Figure 4,
A and B). Consistent with previous studies,1 EPCs were
detected predominantly in the border zone of the infarct, as
evidenced by visualizing neighboring intact cardiac myocytes
with a-sarcomeric actinin (Figure 4B). The endothelial char-
acter was demonstrated further by Ulex europaeus lectin
(Figure 4B). Of note, 96 hours after infarction, EPCs did not
yet form vessel-like structures. However, when animals were
killed 25 days after the EPC injection, DiLDL-labeled EPCs
were integrated and revealed a differentiated phenotype (data
not shown).
In addition, tissue sections of the other organs, in which the
majority of the radioactivity was detected, were analyzed. In
spleen, DiLDL-labeled EPCs were found predominantly in
the marginal zone around lymphoid follicles and in the red
pulp (Figure 4C). In contrast, in liver and kidney, DiLDL-
labeled EPCs were rarely detectable, although ’70% of the
radioactivity remained in these organs. These results were
confirmed by immunostaining for human HLA (data not
shown).
Discussion
The results of our study demonstrate that radiolabeling with
111In-oxine is a useful method for the in vivo monitoring of
the fate of infused progenitor cells. Radioactive labeling does
not seem to affect cell viability or EPC function, as shown by
measurements of LDH release and DiLDL uptake. Further-
more, radioactively labeled EPCs were well incorporated and
revealed a differentiated phenotype in animals 25 days after
infarction.
Our data reveal that the absolute level of intravenously
injected EPCs homing to the heart is ’1% of the injected
radioactivity. Intravenous infusion of EPCs after infarction
increased the number of EPCs in the heart significantly,
Figure 3. A, Distribution of radioactivity in different tissues after
intravenous (top) and intracavitary (bottom) application of 111In-
oxine–labeled EPCs in infarct or sham-operated nude rats 96
hours after EPC therapy. B, Ratio of specific radioactivity in
heart vs skeletal muscle in infarct and sham-operated animals
after intravenous and intracavitary administration of 111In-oxine–
labeled EPCs. Data are given as mean6SD; n58 (infarct) and
n58 (sham).
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’2-fold. This is in accordance with previous studies that
demonstrate that tissue ischemia is a major stimulus for
incorporation of circulating progenitor cells.2–4,14,15 However,
even after infarction, the absolute number of EPCs detected in
the heart is rather low. Thus, the number of cells that can be
isolated from peripheral blood might be one major limitation
for potential cell therapy. Homing of EPCs might be in-
creased by injection of EPCs into the left ventricular cavity.
Indeed, the incorporation of radioactivity into the heart in rats
after myocardial infarction increased significantly, by 4.7-
fold, compared with intravenous injection in sham-operated
animals when EPCs were injected into the left ventricular
cavity. In line with this finding, more EPCs were detectable
by immunostaining and fluorescence microscopy after intra-
cavitary injection (data not shown). One may speculate that
an intracoronary infusion in humans might even further
enhance the local accumulation of progenitor cells in the
myocardium.
At both 1 and 96 hours after injection, radioactivity was
detected predominantly in spleen, liver, and kidneys. Fluo-
rescence microscopy and immunostaining revealed that in the
spleen, intact EPCs localized primarily to lymphoid follicles,
especially around marginal zones, as expected, because the
spleen is known to be the major site for homing of immuno-
competent cells.16–18
In contrast, although the radioactivity was high in liver and
kidneys, EPCs were rarely detectable in these organs after 96
hours. Leakage of 111In from labeled cells has been described
to be the reason for the high uptake of radioactivity in liver
and kidney.19 In lymphocytes, a 70% loss of radioactivity was
reported at 24 hours after cell labeling. Slightly better results
were obtained in our study, with a loss of 61% of 111In from
radiolabeled EPCs in vitro within 48 hours. Because of
excretion through renal and hepatobiliary pathways, these
organs exhibited a high specific activity that was not bound to
EPCs, as confirmed by fluorescence microscopy and immu-
nostaining. The nonspecific tracer signal caused by in vivo
efflux of 111In, however, does not seem to be a major concern
outside the liver and kidneys. The significant difference in
specific heart uptake after myocardial infarction does indeed
represent the tissue distribution of engrafted EPCs, as con-
firmed by colabeling of EPCs with DiLDL.
Figure 4. Distribution of human 111In-oxine–labeled and DiLDL-
labeled EPCs in frozen sections of rat heart and spleen. A, Left,
Phase-contrast images of native sections demonstrate infarcted
area with loss of intact cardiomyocytes (area on right side of
picture). Right, DiLDL1 (red fluorescence) EPCs accumulate spe-
cifically in infarct border zone. B, Immunostaining of cells in
infarct border zone. Left, Human cells were stained by anti-HLA
class I (green fluorescence), endothelial phenotype was con-
firmed by Ulex europaeus lectin staining (red fluorescence), and
a merge of 2 images is shown at bottom, where double-positive
cells appear in yellow. Note that almost all cells stained positive
for Ulex europaeus lectin. Right, Intact cardiac myocytes were
stained by a-sarcomeric actinin (green fluorescence), and
human cells stained with anti-HLA class I antibodies (red fluo-
rescence). Note human EPCs in proximity to intact cardiomyo-
cytes in infarct border zone (C). DiLDL1 EPCs (red fluorescence)
were detected in spleen, which also express human HLA class I
(green fluorescence). Double-positive cells appear in yellow in
merged image (bottom right). EPCs can be found primarily in
marginal zones of lymphoid follicles and in red pulp. Represen-
tative pictures are shown from n53 to 7 individual experiments.
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111In-oxine is a well-known, safe, and commercially avail-
able radioactive tracer for monitoring blood cells, for exam-
ple, leukocytes, for inflammation scintigraphy.6 Regarding
the physical half-life of 111In of 2.8 days, it allows us to follow
up cell distribution for ’5 to 7 days, which we considered a
clear advantage over other tracers, such as 99m[Tc]technetium-
labeled hexamethylpropylene amine oxime (HMPAO), with a
physical half-life of 6 hours. The limitation of 111In, however,
is its high g-energy of 171 and 245 keV, which requires the
use of medium-energy collimators. Although the spatial
resolution (.12 mm) of these collimators is rather poor, it is
sufficient for clinical application in patients. However, in
nude rats with a mean weight of ,200 g and a heart size just
in the range of the collimator resolution, the rather low uptake
of EPCs in the heart cannot be distinguished from the high
tracer accumulation in the adjacent liver and spleen. An
alternative to increase resolution is the use of a pinhole
collimator. In our study, we could show that only pinhole
collimators were appropriate tools to obtain a resolution high
enough to clearly discriminate the increase in radioactivity in
animals with myocardial infarctions. Moreover, for small-
animal studies, the use of positron emission tomography with
a high spatial resolution would be the ideal imaging modal-
ity.20 However, when testing the widely available [18F]flu-
orodeoxyglucose as a label, an insufficient labeling efficiency
of human EPCs was obtained (data not shown). 64Cu has also
been shown to be an alternative positron emission tomogra-
phy tracer for cell labeling, with a potentially suitable
half-life of 12.7 hours,21 but this tracer requires generation by
a cyclotron. Therefore, to extend the feasibility of progenitor
cell transplantation imaging to routine clinical application, we
decided to use 111In-labeled EPCs, despite the limited resolu-
tion in rats, and to combine scintigraphic imaging with in
vitro measurement of tissue specific activities in the heart and
various other organs for this experimental setting.
In summary, the results of this study demonstrate that 111In-oxine
is a useful tracer for in vivo monitoring of transplanted EPCs in a rat
model of myocardial infarction. Thus, radioactive labeling with
111In-oxine may provide a noninvasive imaging approach to assess
the fate and tissue distribution of transplanted progenitor cells
during clinical cell therapy.
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